ClinicalTrials.gg

Program

betamethasone dipropionate

Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.

Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.

Furthest: phase 4, since Nov 3, 200526 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharma180 open or runningphase 4since Nov 3, 2005Sep 15, 2005none ahead
MC2 Therapeutics50 open or runningphase 3since Oct 9, 2017Oct 9, 2017none ahead
Glenmark Pharmaceuticals Ltd. India10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
Huadong Medicine10 open or runningphase 3since Dec 11, 2025Dec 11, 2025none ahead
Primus Pharmaceuticals10 open or runningphase 4since Apr 13, 2016Apr 13, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Sep 15, 2005.

  1. Aug 27, 2013Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT01935869 · 224 enrolled · France
  2. Jan 27, 2015Phase 1 study in Skin and Connective Tissue DiseasesLEO Pharma · NCT02355639 · 16 enrolled · Germany
  3. Feb 25, 2015Phase 1 study in Dermatitis, AtopicLEO Pharma · NCT02376049 · 30 enrolled · Canada, Israel
  4. Mar 12, 2015Phase 2 study in Psoriasis VulgarisLEO Pharma · NCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
  5. Apr 13, 2016Primus Pharmaceuticals’ first study: phase 4 study in Plaque PsoriasisNew to Primus PharmaceuticalsPrimus Pharmaceuticals · NCT02749799 · 45 enrolled · United States
  6. Nov 22, 2016Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT02973776 · 36 enrolled · France
  7. Oct 9, 2017MC2 Therapeutics’ first study: phase 3 study in Psoriasis VulgarisNew to MC2 TherapeuticsMC2 Therapeutics · NCT03308799 · 794 enrolled · United States
  8. Nov 1, 2017Glenmark Pharmaceuticals Ltd. India’s first study: phase 3 study in Scalp PsoriasisNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT03331523 · 643 enrolled · United States
  9. Feb 20, 2018Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03462927 · 63 enrolled · United States
  10. Nov 13, 2018Phase 1 study in VasoconstrictionMC2 Therapeutics · NCT03758365 · 36 enrolled · France
  11. Jan 10, 2019Phase 3 study in Psoriasis VulgarisMC2 Therapeutics · NCT03802344 · 498 enrolled · Czechia, Germany
  12. Jan 11, 2019Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03819218 · 7 enrolled · Czechia, Germany
  13. Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisLEO Pharma · NCT05919082 · 604 enrolled · China
  14. Dec 11, 2025Huadong Medicine’s first study: phase 3 study in Plaque PsoriasisNew to Huadong MedicineHuadong Medicine · NCT07357831 · 539 enrolled · China

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07357831Plaque Psoriasis · China3CompletedHuadong MedicineAug 6, 2026539
NCT05919082Stable Plaque Psoriasis · China3CompletedLEO PharmaFeb 23, 2024604
NCT03819218Psoriasis Vulgaris · Czechia, Germany2TerminatedMC2 TherapeuticsDec 11, 20207
NCT03802344Psoriasis Vulgaris · Czechia, Germany3CompletedMC2 TherapeuticsOct 2, 2019498
NCT03758365Vasoconstriction · France1CompletedMC2 TherapeuticsNov 23, 201836
NCT03462927Psoriasis Vulgaris · United States2CompletedMC2 TherapeuticsAug 4, 201863
NCT03331523Scalp Psoriasis · United States3CompletedGlenmark Pharmaceuticals Ltd. IndiaOct 25, 2018643
NCT03308799Psoriasis Vulgaris · United States3CompletedMC2 TherapeuticsJun 8, 2018794
NCT02973776Psoriasis Vulgaris · France1CompletedLEO PharmaFeb 201736
NCT02749799Plaque Psoriasis · United States4CompletedPrimus PharmaceuticalsJul 201645
NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more2CompletedLEO PharmaMar 28, 2018117
NCT02376049Dermatitis, Atopic · Canada, Israel1CompletedLEO PharmaJul 201530
NCT02355639Skin and Connective Tissue Diseases · Germany1CompletedLEO PharmaApr 201516
NCT01935869Psoriasis Vulgaris · France1CompletedLEO PharmaNov 2013224
NCT01866163Psoriasis Vulgaris · United States3CompletedLEO PharmaOct 2013426
NCT01600222Psoriasis Vulgaris · Canada2CompletedLEO PharmaMay 201337
NCT01536938Psoriasis Vulgaris · United States2CompletedLEO PharmaSep 2012303
NCT01536886Psoriasis Vulgaris · United States2CompletedLEO PharmaSep 2012376
NCT00875277Psoriasis Vulgaris · France2CompletedLEO PharmaMay 200924
NCT00817219Psoriasis Vulgaris · United States2CompletedLEO PharmaDec 201133
NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more2CompletedLEO Pharma360
NCT00248456Psoriasis Vulgaris · China4CompletedLEO Pharma320
NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more3CompletedLEO Pharma300
NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more3CompletedLEO Pharma800
NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more3CompletedLEO Pharma1,350
NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more3CompletedLEO Pharma1,485

How it is read

Names in the registry

  • “LEO 90100”, 7 entries
  • “MC2-01 cream”, 4 entries
  • “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
  • “MC2-01 Cream”, 2 entries
  • “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.